SIMPLIFY HEALTH CARE ETF(PINK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PINK SIMPLIFY HEALTH CARE ETF

未开盘 10-13 16:00:00 EDT

37.79

-0.69

-1.79%

盘后37.79

+0.000.00%

19:30 EDT

最高38.51	最低37.72	成交量1.84万
今开38.51	昨收38.48	日振幅2.05%
总市值3.14亿	流通市值3.14亿	总股本830.00万
成交额69.74万	换手率0.22%	流通股本830.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PINK","market":"US","secType":"STK","nameCN":"SIMPLIFY HEALTH CARE ETF","latestPrice":37.79,"timestamp":1791921600000,"preClose":38.48,"halted":0,"volume":18400,"hourTrading":{"tag":"盘后","latestPrice":37.79,"preClose":37.79,"latestTime":"19:30 EDT","volume":10,"amount":377.9,"timestamp":1791934204786,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.017931392931392873,"floatShares":8300001,"shares":8300001,"eps":0,"marketStatus":"未开盘","change":-0.69,"latestTime":"10-13 16:00:00 EDT","open":38.51,"high":38.51,"low":37.72,"amount":697381.896,"amplitude":0.02053,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":38.48,"sharesOutstanding":7975001,"nav":38.4622,"aum":318224671.01,"dividendRate":0.007952,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.79,"preClose":37.79,"latestTime":"19:30 EDT","volume":10,"amount":377.9,"timestamp":1791934204786,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.094476,"impliedVol":0.145,"impliedVolPercentile":0.7888},"requestUrl":"/m/hq/s/PINK/wiki","defaultTab":"wiki","newsList":[{"id":"2674571328","title":"国产减肥药公布积极研究数据，GLP-1药物进入长效竞争？","url":"https://stock-news.laohu8.com/highlight/detail?id=2674571328","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674571328?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:41","pubTimestamp":1791553260,"startTime":"0","endTime":"0","summary":"10月9日，广东众生药业股份有限公司（众生药业，002317）10%涨停。消息面上，10月8日晚间，众生药业发布公告称，控股子公司广东众生睿创生物科技有限公司（简称“众生睿创”）自主研发的一类创新多肽药物RAY1225注射液在超重或肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的三期临床试验，于近日获得顶线分析数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093891510724.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093891510724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NBDS","RSPH","XLVI","NVOH","FHLC","TRUH","NVOX","MEDI","NVOC","PINK","PJP","CURE","IYH","JDOC","FXH","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673891024","title":"减肥药还能抗衰老？第一款大众抗衰药可能正在路上","url":"https://stock-news.laohu8.com/highlight/detail?id=2673891024","media":"麻省理工科技评论","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673891024?lang=zh_cn&edition=full","pubTime":"2026-10-08 15:36","pubTimestamp":1791444960,"startTime":"0","endTime":"0","summary":"热门减肥药可能不只可以帮助人们减掉体重，还可能让岁月的痕迹一同消退。他被认为是“衰老时钟”的发明者之一。它们能够改善肾功能、降低血压，甚至显著降低总体死亡风险。诺和诺德发现，随着时间推移，这些药物能够让多种衰老时钟显示出衰老减缓的迹象。多位与会者提醒，GLP-1 类药物确实存在副作用，其中包括肌肉流失。与此同时，该项目还希望帮助建立针对抗衰老药物的监管路径，并围绕长寿领域“建立一个新的治疗产业”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8x3ZZsOsIiW","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["PJP","PINK","THNR","XLVI","NBDS","RSPH","NVOH","CURE","NVOC","FXH","IYH","FHLC","MEDI","TRUH","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673808042","title":"Zealand Pharma与罗氏在研减肥药中期临床试验帮助患者减重高达9.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673808042","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673808042?lang=zh_cn&edition=full","pubTime":"2026-10-08 10:37","pubTimestamp":1791427037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MDTX","TRUH","FHLC","PINK","RSPH","FXH","CURE","MEDI","NVOH","PJP","IBBQ","THNR","XLVI","PSYK","NBDS","IYH","BMED","IBBJ","NVOC","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671772271","title":"2026诺奖前瞻：GLP-1减肥药背后的科学家成热门人选","url":"https://stock-news.laohu8.com/highlight/detail?id=2671772271","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671772271?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:07","pubTimestamp":1790755679,"startTime":"0","endTime":"0","summary":"来源：环球市场播报2026年诺奖得主将于10月5日至12日陆续公布。值得注意的是，此次的诺奖预测中，有五位被提及的生理学或医学奖潜在人选均与GLP-1研究及相关药物开发密切相关。Lotte Bjerre Knudsen是药物科学家，在诺和诺德任职期间，挖掘了GLP-1在糖尿病和体重管理领域的潜力，她是2025年生命科学突破奖得主。哈佛大学生物化学家David Liu，为2025年生命科学突破奖得主。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/09/30160758594138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["JDOC","NBDS","FXH","MEDI","TRUH","LLII","OZEM","NVOH","PJP","LLYX","ELIL","PINK","ELIS","THNR","CURE","XLVI","RSPH","NVOC","NVOX","FHLC","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671827131","title":"2026诺奖前瞻：GLP-1减肥药背后的科学家成热门人选","url":"https://stock-news.laohu8.com/highlight/detail?id=2671827131","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671827131?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:56","pubTimestamp":1790754987,"startTime":"0","endTime":"0","summary":"2026年诺奖得主将于10月5日至12日陆续公布。为了解热门候选名单，《The Scientist》刊发了科学家们对2026年诺贝尔生理学或医学奖、物理学奖、化学奖得主的预测。值得注意的是，此次的诺奖预测中，有五位被提及的医学奖潜在人选均与GLP-1研究及相关药物开发密切相关。Lotte Bjerre Knudsen是药物科学家，在诺和诺德任职期间，挖掘了GLP-1在糖尿病和体重管理领域的潜力，她是2025年生命科学突破奖得主。哈佛大学生物化学家David Liu，为2025年生命科学突破奖得主。","market":"us","thumbnail":"https://n.sinaimg.cn/finance/transform/79/w550h329/20260930/d305-020e775d38bcdf7e36c23a699d390096.png","type":0,"news_type":0,"thumbnails":["https://n.sinaimg.cn/finance/transform/79/w550h329/20260930/d305-020e775d38bcdf7e36c23a699d390096.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-30/doc-initqzmc5708551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["ELIS","IYH","THNR","LLYX","XLVI","NBDS","PJP","CURE","MEDI","FXH","OZEM","TRUH","NVOX","NVOH","PINK","LLII","RSPH","FHLC","NVOC","ELIL","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671279010","title":"2026诺奖前瞻：GLP-1减肥药背后的科学家成热门人选","url":"https://stock-news.laohu8.com/highlight/detail?id=2671279010","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671279010?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:51","pubTimestamp":1790754672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LLYX","NVOH","ELIL","MEDI","ELIS","NVOC","OZEM","IYH","CURE","XLVI","TRUH","JDOC","FXH","NBDS","THNR","RSPH","LLII","PJP","FHLC","PINK","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671524876","title":"交易额最高可达26亿美元！诺和诺德买下恒瑞“每周一次口服”减肥药 两大外资药企巨头周制剂布局均靠“外援”","url":"https://stock-news.laohu8.com/highlight/detail?id=2671524876","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671524876?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:37","pubTimestamp":1790692650,"startTime":"0","endTime":"0","summary":"9月29日，恒瑞医药（SH600276，股价45.62元，总市值3028亿元）公告称，公司将潜在每周一次口服给药的胰高血糖素样肽-1（GLP-1）和抑胃肽（GIP）双受体激动剂HRS-1596有偿许可给诺和诺德。诺和诺德将获得HRS-1596在大中华地区以外的全球范围内开发、生产和商业化的独家权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886793117.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886793117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVOX","THNR","RSPH","NVOH","BGIA","CURE","PINK","MEDI","XLVI","TRUH","PJP","NVOC","FHLC","NBDS","IYH","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671216897","title":"礼来：减肥药Zepbound 10毫克和15毫克剂型因不良反应停药的比例与Wegovy高剂量组相当。","url":"https://stock-news.laohu8.com/highlight/detail?id=2671216897","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671216897?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:02","pubTimestamp":1790679728,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RSPH","XLVI","THNR","CURE","TRUH","FHLC","MEDI","PINK","NVOC","NVOH","PJP","NBDS","FXH","IYH","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669570944","title":"A股节前全天缩量震荡 深成指收跌2.34% 减肥药、电子烟板块疲软","url":"https://stock-news.laohu8.com/highlight/detail?id=2669570944","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669570944?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:11","pubTimestamp":1790233888,"startTime":"0","endTime":"0","summary":"金吾财讯 | A股中秋节前全天缩量震荡，午后跌幅进一步扩大，整体交投情绪继续下降，截至收盘，沪指跌1.22%，深成指跌2.34%，创业板指跌2.68%。板块方面，先进封装、减肥药、CPO、电子烟等板块跌幅居前；教育、航运港口、煤炭、工程机械等板块涨幅居前。国投证券表示，若节前成交不足，行情仍需依靠部分行业和个股带动。偏债转债的纯债溢价率仍低于2021至2023年的中枢，但上周已由12.3%回升至13.0%，110只低平价样本中仅13只到期收益率为正。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NzYyNDljMmIwNjZjMTQ3MTljY2ZkYmY1MDAwNDcwMjMxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992454","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSPH","82846","XLVI","399300","BK1242","NVOC","BK1147","TRUH","PINK","83130","159982","BK1589","NBDS","FHLC","THNR","06969","NVOX","83188","02846","NVOH","BK1580","IYH","399001","PJP","CURE","03188","07233","02827","MEDI","03130","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669172514","title":"诺和诺德对升级其纽约上市地位的想法持开放态度，这是这家丹麦减肥药制造商提升其在美国知名度努力的一部分，其英国竞争对手阿斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2669172514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669172514?lang=zh_cn&edition=full","pubTime":"2026-09-23 12:15","pubTimestamp":1790136902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOX","RSPH","BGIA","NVOC","PJP","TRUH","MEDI","XLVI","PINK","CURE","THNR","IYH","FXH","NBDS","NVOH","IPOS","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142648","title":"Viking Therapeutics涨超35%！减肥药传来捷报：给药频率减半仍维持97%减重","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142648","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669142648?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:50","pubTimestamp":1790085009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Viking Therapeutics周二盘前一度飙升近50%，此前这家生物科技公司宣布，其实验性肥胖症药物VK2735帮助患者在用药频率从每周一次降至每两周一次的情况下，仍维持了大部分减重成果。这一结果有望进一步增强VK2735在快速扩张的减肥药市场中的竞争地位。截至发稿，VKTX股价上涨近23%。今年以来，该股累计下跌约15%。据了解，VK2735是Viking的主要肥胖症候选药物，正在开发注射剂和口服剂两种剂型。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499522.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVOH","FHLC","CURE","PJP","BK4585","BK4139","OZEM","BK4007","RSPH","THNR","NBDS","PINK","VKTX","BK4588","BK4599","NVOC","BK4539","IYH","FXH","NVOX","TRUH","XLVI","MEDI","LENZ"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2669633164","title":"减肥药巨头，裁掉了1.3万个岗位","url":"https://stock-news.laohu8.com/highlight/detail?id=2669633164","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669633164?lang=zh_cn&edition=full","pubTime":"2026-09-21 23:20","pubTimestamp":1790004000,"startTime":"0","endTime":"0","summary":"诺和诺德方面表示，通过本轮组织调整，公司节约成本超100亿丹麦克朗，帮助公司重新投向商业化与研发；过往调整累计涉及约1.3万个岗位，目前全球全职员工为6.6万人。2026年上半年，诺和诺德司美格鲁肽产品组合，合计销售额为1121.93亿丹麦克朗，收入已落后竞品礼来的替尔泊肽约102亿美元。在这一阶段，竞争格局将达到顶峰，企业需要在专利到期的司美格鲁肽与下一代肥胖治疗药物之间进行战略定位。本次资本日，诺和诺德公布了2030战略雄心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-21/doc-inisrhfv9159432.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-21/doc-inisrhfv9159432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CURE","MEDI","NBDS","XLVI","FHLC","TRUH","PJP","PINK","NVOX","THNR","NVOC","IYH","NVOH","RSPH","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669318161","title":"减肥药巨头诺和诺德本轮调整，裁掉了1.3万个岗位","url":"https://stock-news.laohu8.com/highlight/detail?id=2669318161","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669318161?lang=zh_cn&edition=full","pubTime":"2026-09-21 22:08","pubTimestamp":1789999702,"startTime":"0","endTime":"0","summary":"去年9月份宣布要裁员9000人的诺和诺德，于9月21日在伦敦举办的资本市场日上披露了最终减员情况。诺和诺德方面表示，通过本轮组织调整，公司节约成本超100亿（15.35亿美元）丹麦克朗，帮助公司重新投向商业化与研发；过往调整累计涉及约1.3万个岗位，目前全球全职员工为6.6万人。诺和诺德本轮人员优化背后，核心动因是支撑公司七成以上营收的王牌产品司美格鲁肽，正面临增长承压的挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880315953.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880315953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FHLC","IYH","THNR","NVOC","MEDI","NBDS","NVOX","NVOH","FXH","PJP","RSPH","CURE","BGIA","PINK","TRUH","XLVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669759159","title":"注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2669759159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669759159?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:54","pubTimestamp":1789980888,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CURE","MEDI","PINK","PJP","TRUH","NVOH","NVOC","NVOX","THNR","BGIA","NBDS","FHLC","XLVI","IYH","RSPH","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669590351","title":"注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2669590351","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669590351?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:53","pubTimestamp":1789980780,"startTime":"0","endTime":"0","summary":"一起美国的诉讼，让GLP-1药物的安全性再次受到行业关注。据外媒报道称，自2025年以来，一律所代表患者在美国新泽西州州法院提起了90多起诉讼，其起诉的对象是明星GLP-1药物司美格鲁肽背后的药企诺和诺德，原因是其在使用降糖版司美格鲁肽之后被诊断为非动脉炎性前部缺血性视神经病变（简称NAION）。上述报道指出，礼来的GLP-1药物替尔泊肽也面临患者针对NAION风险提起的诉讼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880057798.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880057798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CURE","NVOH","RSPH","PINK","IYH","NVOX","TRUH","FHLC","BGIA","XLVI","NBDS","NVOC","PJP","FXH","MEDI","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311633","title":"诺和诺德(NVO.US)减肥药拓展低龄市场：STEP Young试验显示司美格鲁肽显著降低儿童肥胖率","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311633","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665311633?lang=zh_cn&edition=full","pubTime":"2026-09-07 20:15","pubTimestamp":1788783311,"startTime":"0","endTime":"0","summary":"诺和诺德在声明中指出，这项名为STEP Young的试验所纳入的全部受试者，在整个研究期间均接受了生活方式干预，包括限制热量摄入和增加体育锻炼。诺和诺德首席科学官马丁·霍尔斯特·兰格表示：“STEP Young试验的积极结果令人振奋，我们看好司美格鲁肽在帮助罹患肥胖的儿童方面的潜力——这些儿童除生活方式调整外，尚需药物治疗以更有效地管理其肥胖状况。”","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BGIA","NBDS","NVOH","THNR","PJP","RSPH","TRUH","XLVI","NVOX","FHLC","IYH","PINK","MEDI","NVOC","FXH","CURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311616","title":"诺和诺德(NVO.US)减肥药拓展低龄市场：STEP Young试验显示司美格鲁肽显著降低儿童肥胖率","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311616","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665311616?lang=zh_cn&edition=full","pubTime":"2026-09-07 20:15","pubTimestamp":1788783311,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDI","FXH","RSPH","TRUH","PINK","THNR","BGIA","XLVI","IYH","CURE","NVOC","NVOH","FHLC","NVOX","PJP","NBDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882140","title":"Hims & Hers在澳大利亚推出GLP-1减肥药及治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882140","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664882140?lang=zh_cn&edition=full","pubTime":"2026-09-01 10:10","pubTimestamp":1788228656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["RSPH","NVOH","XLVI","OZEM","CURE","IYH","LLYX","LLII","NBDS","NVOX","PJP","ELIL","THNR","TRUH","JDOC","PINK","FHLC","ELIS","FXH","NVOC","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006809","title":"不止步于“减肥药之王” 礼来(LLY.US)拟最高28.8亿美元收购Merida加码自身免疫赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006809","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663006809?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:12","pubTimestamp":1788181963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼来计划以高达28.8亿美元的现金收购Merida Biosciences Inc.，加码自身免疫与过敏疾病领域，以摆脱对减重和糖尿病两大支柱业务的过度依赖——正是这两大市场助其登顶全球药企市值之巅。今年以来，礼来掀起并购狂潮，迄今已宣布的交易总额超过200亿美元。5月，礼来还达成协议，以最高38亿美元收购三家疫苗研发企业。截至发稿，礼来盘前跌0.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FHLC","PINK","XLVI","NVOC","MEDI","IYH","NVOH","RSPH","TRUH","NVOX","PJP","THNR","NBDS","FXH","CURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006800","title":"不止步于“减肥药之王” 礼来(LLY.US)拟最高28.8亿美元收购Merida加码自身免疫赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006800","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663006800?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:12","pubTimestamp":1788181963,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IYH","NVOC","RSPH","XLVI","NVOH","PJP","FXH","PINK","CURE","FHLC","NBDS","TRUH","THNR","NVOX","MEDI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0016},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0126},{"period":"6month","weight":0.0785},{"period":"1year","weight":0.1902},{"period":"ytd","weight":0.0514}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012643},{"month":2,"riseRate":0.6,"avgChangeRate":0.005136},{"month":3,"riseRate":0.6,"avgChangeRate":-0.001509},{"month":4,"riseRate":0.6,"avgChangeRate":-0.008129},{"month":5,"riseRate":0.6,"avgChangeRate":0.008295},{"month":6,"riseRate":0.8,"avgChangeRate":0.032925},{"month":7,"riseRate":0.6,"avgChangeRate":0.011634},{"month":8,"riseRate":0.6,"avgChangeRate":0.002039},{"month":9,"riseRate":0.2,"avgChangeRate":-0.01329},{"month":10,"riseRate":0.4,"avgChangeRate":0.014179},{"month":11,"riseRate":0.8,"avgChangeRate":0.042023},{"month":12,"riseRate":0.4,"avgChangeRate":0.008788}],"exchange":"ARCA","name":"SIMPLIFY HEALTH CARE ETF","nameEN":"SIMPLIFY HEALTH CARE ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SIMPLIFY HEALTH CARE ETF(PINK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SIMPLIFY HEALTH CARE ETF(PINK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SIMPLIFY HEALTH CARE ETF,PINK,SIMPLIFY HEALTH CARE ETF股票,SIMPLIFY HEALTH CARE ETF股票老虎,SIMPLIFY HEALTH CARE ETF股票老虎国际,SIMPLIFY HEALTH CARE ETF行情,SIMPLIFY HEALTH CARE ETF股票行情,SIMPLIFY HEALTH CARE ETF股价,SIMPLIFY HEALTH CARE ETF股市,SIMPLIFY HEALTH CARE ETF股票价格,SIMPLIFY HEALTH CARE ETF股票交易,SIMPLIFY HEALTH CARE ETF股票购买,SIMPLIFY HEALTH CARE ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SIMPLIFY HEALTH CARE ETF(PINK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SIMPLIFY HEALTH CARE ETF(PINK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}